Victor J. Dzau, MD, is the President of the US National Academy of Medicine (NAM), and serves as Vice Chair of the US National Research Council. Professor Dzau is Chancellor Emeritus of the Duke University. Previously, he was Chairman of Medicine at Harvard, as well as Stanford Universities. Professor Dzau is highly regarded as a trailblazer in translational research, health innovation, and global health. His seminal work laid the foundation for development of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Professor Dzau pioneered gene therapy for vascular disease. As one of the world’s preeminent health leaders, he has served as Chair of the NIH Cardiovascular Disease Advisory Committee and now chairs the NIH Cardiovascular Stem Cell Consortium. Currently he is a member of Health Biomedical Sciences Advisory Council of Singapore and was on the Board of Health Governors of the World Economic Forum and chairs its Council on Human Longevity and Enhancement.  Professor Dzau is active in Global Health. He serves on Global Preparedness Monitoring Board (GPMB), Steering Group of the Global Access to COVID Tools Accelerator, and was on the interim board of CEPI. Leading the National Academy of Medicine, Professor Dzau has launched important initiatives such as the Global Health Risk Framework (2016), the Global Health and the Future Role of the US (2017), Integrating Clinical Research into Epidemic Response: The Ebola Experience (2017); Crossing the Global Quality Chasm (2018), Human Gene Editing (2017) and the NAM Grand Challenge in Healthy Longevity.